Metropolis Healthcare Ltd

Metropolis Healthcare announced that the 26th Annual General Meeting(AGM) of the company will be held on 18 August 2026.

Metropolis Healthcare has allotted 36,900 equity shares under he Metropolis-Restrictive Stock Unit Plan, 2020 on 09 July 2026.

The company said the TruHealth Wellness and Specialty segments are the fastest growing segments for the quarter. In B2C business registered healthy volume growth, driven by increased throughput from the expanded center network. B2B volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels. The company said EBITDA margins improved on a YoY basis in line with guidance. On quarter-on-quarter basis, margins remained largely stable. During the Q4 earnings call, promoter Ameer Shah said the company has guided for a sustainable group EBITDA margin of 27%'28% over the next three years. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. The company's consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live

Aadhar Housing Finance Ltd, Black Box Ltd, Tata Capital Ltd and Craftsman Automation Ltd are among the other losers in the BSE's 'A' group today, 22 June 2026.Metropolis Healthcare Ltd tumbled 4.49% to Rs 527.4 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9318 shares were traded on the counter so far as against the average daily volumes of 8023 shares in the past one month.Aadhar Housing Finance Ltd crashed 4.09% to Rs 494.5. The stock was the second biggest loser in 'A' group.On the BSE, 44078 shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month.Black Box Ltd lost 3.95% to Rs 982.4. The stock was the third biggest loser in 'A' group.On the BSE, 27012 shares were traded on the counter so far as against the average daily volumes of 48825 shares in the past one month.Tata Capital Ltd fell 3.86% to Rs 357.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 3.99 lakh shares were traded on the counter so far as against the average daily volumes of 3.8 lakh shares in the past one month.Craftsman Automation Ltd dropped 3.80% to Rs 9478.85. The stock was the fifth biggest loser in 'A' group.On the BSE, 11122 shares were traded on the counter so far as against the average daily volumes of 10180 shares in the past one month.Powered by Capital Market - Live

Metropolis Healthcare announced that the Board of Directors of the Company at its meeting held on 13 May 2026, inter alia, have recommended the Second Interim dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Profit before exceptional items and tax climbed 93.26% YoY to Rs 69.65 crore in the quarter ended 31st March 2026. The company reported an exceptional loss of Rs 10.69 crore during the quarter. EBITDA stood at Rs 108 crore in Q4 FY26, up 71.3% compared with Rs 63 crore posted in Q4 FY25. EBITDA margin improved to 25.4% in Q4 FY26 as against 18.5% in Q4 FY25. During the quarter, patient volumes grew 11% YoY to 3.5 million, and test volumes increased 14% YoY to 7.6 million, reflecting sustained demand momentum, deeper market penetration and stronger clinician engagement. Revenue per Patient (RPP) improved 11% YoY to Rs 1,210, while Revenue per Test (RPT) increased 8% YoY to Rs 558, supported by favourable mix and higher contribution from specialised testing. The company's B2C revenues grew 20% YoY to Rs 251 crore, driven by higher adoption of preventive and specialized testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% YoY to Rs 174 crore, aided by strong client retention, hospital outsourcing opportunities, deeper partner relationships and improved service reliability. On a full year basis, the company's consolidated net profit climbed 31.08% to Rs 190.01 crore on 23.64% rise in revenue from operations to Rs 1,645.84 crore in FY26 over FY25. Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said, 'The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.' Surendran Chemmenkotil, managing director, Metropolis Healthcare, said, 'FY26 was an important year from an execution and operating transformation standpoint for Metropolis. Growth during the year was driven by healthy patient volumes, improved mix and stronger realisations, without any price increase in Q4, reflecting the strength of the underlying demand environment. We also made steady progress in productivity, network utilisation, lab optimisation and acquisition integration, supporting operating leverage and meaningful margin expansion. Going forward, we remain focused on driving sustainable growth, improving network throughput and delivering further efficiency-led margin expansion over the medium term.' Meanwhile, the company's board declared 2nd interim dividend of Rs 1 per equity share of face value Rs 2 each for the financial year 2025-26. The record date for the purpose of payment of interim dividend shall be Tuesday, May 19, 2026. The dividend will be paid within 30 days of its declaration. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics.Powered by Capital Market - Live

Net profit of Metropolis Healthcare rose 74.67% to Rs 50.90 crore in the quarter ended March 2026 as against Rs 29.14 crore during the previous quarter ended March 2025. Sales rose 22.99% to Rs 424.68 crore in the quarter ended March 2026 as against Rs 345.29 crore during the previous quarter ended March 2025. For the full year,net profit rose 31.08% to Rs 190.02 crore in the year ended March 2026 as against Rs 144.97 crore during the previous year ended March 2025. Sales rose 23.64% to Rs 1645.85 crore in the year ended March 2026 as against Rs 1331.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales424.68345.29 23 1645.851331.20 24 OPM %25.4418.04 -24.3622.76 - PBDT108.2464.67 67 401.89299.53 34 PBT69.6536.04 93 268.17190.85 41 NP50.9029.14 75 190.02144.97 31 Powered by Capital Market - Live

Metropolis Healthcare has allotted 4,200 equity shares under Metropolis-Restrictive Stock Unit Plan, 2020 on 13 May 2026. With this allotment, the paid up equity share capital has increased to 20,73,31,968 equity shares of Rs 2 each.

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Additionally, the company recorded robust growth across both its B2B and B2C channels, supported by a balanced combination of increased volumes and product mix improvements. B2C revenue grew by around 19% and B2B revenue by approximately 30% on YoY basis, driven by strong specialty growth and a higher B2B contribution in core diagnostics; additionally, TruHealth Wellness and specialty segments recorded growth of around 25% and approsimately 29%, respectively on Y-o-Y basis in Q4 FY26. Excluding the recent acquisitions of Core Diagnostics, DAPIC, Scientific and Ambika, revenue grew by around 14.5% YoY, largely on account of increased patient and test volume, and product mix. EBITDA margins for the quarter improved on a Y-o-Y basis, driven by operating leverage and efficiency gains. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. On a consolidated basis, profit after tax (PAT) rose 33.7% YoY to Rs 42 crore in Q3FY26, compared with Rs 31 crore in Q3FY25. Revenue from operations increased 25.8% YoY to Rs 406 crore in Q3FY26, compared with Rs 323 crore in Q3FY25. The scrip shed 0.20% to end at Rs 422.95 on the BSE. The stock market will remain closed today, 4 April 2026, on account of Good Friday.